Literature DB >> 19237157

Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study.

A Sandhofer1, T Tatarczyk, R Kirchmair, B Iglseder, B Paulweber, J R Patsch, P Schratzberger.   

Abstract

AIMS: Vascular endothelial growth factor (VEGF) is a potent hypoxia-regulated angiogenic factor. Its soluble receptor soluble (s)Flt-1 binds VEGF with high affinity inhibiting the angiogenic function of VEGF. The role of circulating VEGF in atherosclerosis is unclear. METHODS AND
RESULTS: In 909 healthy subjects (511 male, 398 female) from the Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk (SAPHIR) we determined fasting plasma VEGF and sFlt-1 concentration, cardiovascular risk factors and carotid atherosclerosis. VEGF levels were lower and sFlt-1 levels higher in men than in women. VEGF and sFlt-1 showed a positive correlation. In the entire population VEGF correlated positively with age, BMI, insulin resistance, white blood cell and platelet count, C-reactive protein (CRP) and carotid intima media thickness (IMT). After adjustment for age, VEGF showed a weak positive correlation with BMI, liver enzymes, CRP and platelet count in males. In females VEGF correlated negatively with LDL-cholesterol and positively with insulin resistance and platelet count. After adjustment for age, no significant correlation with carotid atherosclerosis could be detected.
CONCLUSION: Plasma VEGF and sFlt-1 are only weakly correlated with cardiovascular risk factors, suggesting that circulating VEGF levels do have only a minor impact on the development of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19237157     DOI: 10.1016/j.atherosclerosis.2009.01.031

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  14 in total

1.  Association of vascular endothelial factors with cardiovascular outcome and mortality in chronic kidney disease patients: a 4-year cohort study.

Authors:  Mehdi Rambod; Gunnar H Heine; Sarah Seiler; Elizabeth A Dominic; Kyrill S Rogacev; Rama Dwivedi; Ali Ramezani; Maria R Wing; Richard L Amdur; Danilo Fliser; Dominic S Raj
Journal:  Atherosclerosis       Date:  2014-08-12       Impact factor: 5.162

2.  Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia.

Authors:  Radosław Wieczór; Anna Maria Wieczór; Grażyna Gadomska; Katarzyna Stankowska; Jacek Fabisiak; Karol Suppan; Grzegorz Pulkowski; Jacek Budzyński; Danuta Rość
Journal:  J Zhejiang Univ Sci B       Date:  2016 Nov.       Impact factor: 3.066

3.  Association between the polymorphisms of the vascular endothelial growth factor gene and metabolic syndrome.

Authors:  Young Ree Kim; Seung-Ho Hong
Journal:  Biomed Rep       Date:  2015-02-04

4.  Relation of vascular growth factors with CT-derived measures of body fat distribution: the Framingham Heart Study.

Authors:  Bernhard M Kaess; Alison Pedley; Joseph M Massaro; Martin G Larson; Erin Corsini; Udo Hoffmann; Holly M Smith; Douglas B Sawyer; Ramachandran S Vasan; Caroline S Fox
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

5.  A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C.

Authors:  Maria G Stathopoulou; Amélie Bonnefond; Ndeye Coumba Ndiaye; Mohsen Azimi-Nezhad; Said El Shamieh; Abdelsalam Saleh; Marc Rancier; Gerard Siest; John Lamont; Peter Fitzgerald; Sophie Visvikis-Siest
Journal:  J Lipid Res       Date:  2012-12-02       Impact factor: 5.922

6.  Serum brain-derived neurotrophic factor and vascular endothelial growth factor levels are associated with risk of stroke and vascular brain injury: Framingham Study.

Authors:  Aleksandra Pikula; Alexa S Beiser; Tai C Chen; Sarah R Preis; Demetrios Vorgias; Charles DeCarli; Rhoda Au; Margaret Kelly-Hayes; Carlos S Kase; Philip A Wolf; Ramachandran S Vasan; Sudha Seshadri
Journal:  Stroke       Date:  2013-08-08       Impact factor: 7.914

7.  The association of serum vascular endothelial growth factor and ferritin in diabetic microvascular disease.

Authors:  Li Guo; Fang Jiang; Yue-Ting Tang; Meng-Ya Si; Xiao-Yang Jiao
Journal:  Diabetes Technol Ther       Date:  2013-11-26       Impact factor: 6.118

8.  Evidence for a relationship between VEGF and BMI independent of insulin sensitivity by glucose clamp procedure in a homogenous group healthy young men.

Authors:  Michaela Loebig; Johanna Klement; André Schmoller; Simone Betz; Nicole Heuck; Ulrich Schweiger; Achim Peters; Bernd Schultes; Kerstin M Oltmanns
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

9.  Coronary angiogenesis during experimental hypertension: is it reversible?

Authors:  Mohammad Zarei; Majid Khazaei; Mohammad Reza Sharifi; Ali Asghar Pourshanazari
Journal:  J Res Med Sci       Date:  2011-03       Impact factor: 1.852

10.  Distinct characteristics of circulating vascular endothelial growth factor-a and C levels in human subjects.

Authors:  Hiromichi Wada; Shuichi Ura; Shuji Kitaoka; Noriko Satoh-Asahara; Takahiro Horie; Koh Ono; Tomohide Takaya; Rieko Takanabe-Mori; Masaharu Akao; Mitsuru Abe; Tatsuya Morimoto; Toshinori Murayama; Masayuki Yokode; Masatoshi Fujita; Akira Shimatsu; Koji Hasegawa
Journal:  PLoS One       Date:  2011-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.